slides · global inventory
Testimonial
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 3,034
Current window 1,831-1,860
Pages 102
Rows per page 30
Slide type
1,831-1,860 of 3,034
190
The slide uses a 'villain critique' style by highlighting the defection of key opinion leaders (KOLs) from the subject company to a competitor.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
203
The slide uses a series of testimonials to undermine the company's growth narrative.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
239
The slide uses a direct quote from a KOL to support the thesis that Nevro reps are overstepping their professional boundaries.Nevro Corp. (NVRO) · Kir Kahlon
Activist deck Short seller 1 hit
03
The slide uses anonymous expert/employee testimony to undermine the credibility of the company's CEO and technical progress.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller 1 hit
04
The slide uses anonymous expert testimony to undermine the company's credibility.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller 1 hit
03
The slide uses anonymous expert testimony to undermine the company's clinical trial integrity and market prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
04
The slide uses a direct user testimonial to highlight product safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
05
The slide presents anecdotal evidence of medical side effects to support an activist narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
06
The slide uses a social media post as a testimonial to highlight negative patient outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
26
The slide uses anecdotal evidence from online discussion groups to highlight patient safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
27
The slide uses screenshots of Facebook group discussions to provide anecdotal evidence of adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
30
The slide uses direct quotes from Facebook groups to undermine the product's safety/efficacy narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
31
The slide uses direct quotes from a Facebook discussion group to highlight the patient/caregiver pain point of symptom detection.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
74
The slide uses direct quotes to undermine the credibility of the drug's approval and market demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
76
The slide uses a direct quote to highlight medical risks that could limit the drug's market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
78
The slide uses direct quotes to highlight a lack of industry awareness and clinical skepticism regarding the drug's mechanism and efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
79
The slide uses direct quotes to highlight the expert's negative sentiment and lack of awareness/enthusiasm for the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
80
The slide highlights the risk of off-label substitution for the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
82
The slide uses direct quotes to undermine the company's marketing claims and highlight physician concerns regarding side effects like diabetes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
83
The slide uses direct quotes from an expert to undermine the company's clinical narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
87
The slide uses direct quotes to validate the activist's thesis regarding the drug's risks and market limitations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
91
The slide uses direct quotes to highlight expert skepticism regarding safety, efficacy, and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
94
This slide presents qualitative feedback from a medical expert, highlighting significant barriers to adoption for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
95
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
97
The slide uses direct quotes to undermine the clinical value and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
98
The slide uses a direct quote to highlight the physician's negative sentiment regarding the drug's value proposition versus the administrative effort required.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
102
The slide uses direct quotes to support the thesis that generic substitution is likely and that GLP-1s are effective.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
151
The slide uses expert testimony to highlight a potential safety concern (edema) and suggests the company is downplaying or managing it in an unusual way.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
161
The slide uses anecdotal evidence from Facebook groups to highlight negative side effects (hyperphagia, behavioral changes) associated with the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
166
The slide uses anecdotal evidence from Facebook discussion groups to highlight potential adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit